- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03150602
A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy
A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Peripheral T-cell lymphomas (PTCL) are a group of aggressive and diverse lymphoproliferative disorders. It is characterized by the presence of malignant mature T-cells or NK cells. There is as yet no consensus regarding standard frontline or relapsed/refractory therapy for PTCL.
A previous phase II study conducted in US showed durable responses of pralatrexate treatment in relapsed or refractory PTCL, irrespective of age, histological subtypes, amount of prior therapy, prior methotrexate, and prior autologous stem-cell transplant. This single-arm, multi-center study aims to evaluate the efficacy and safety of pralatrexate monotherapy in prior treatment failure PTCL patients who may undergo HSCT in case of CR or PR, or continue pralatrexate in case of CR, PR or SD.
Primary objective:
- To evaluate the objective response rate to pralatrexate in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)
Secondary objectives:
To determine the safety of pralatrexate in Asian PTCL patients by,
- Incidence of adverse events (AEs) and serious adverse events (SAEs) emergent from the treatment
To evaluate the efficacy of pralatrexate in Asian PTCL patients after prior treatment failure by,
- Overall survival (OS), progression-free-survival (PFS), complete response (CR) and partial response (PR) rate, and duration of CR and PR
- Treatment duration with pralatrexate in the patients without hematopoietic stem cell transplant (HSCT) who achieve CR or PR
- Percentage of patients who undergo HSCT
- 1-year OS, 1-year PFS, and 1-year relapse rate after HSCT
- 2-year OS, 2-year PFS, and 2-year relapse rate after HSCT
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Bor-Sheng Ko, PhD
- Phone Number: 63576 886-23123456
- Email: kevinkomd@gmail.com
Study Contact Backup
- Name: Brook Chung, MSc
- Phone Number: 886-87297521
- Email: brook.chung@mundipharma.com.tw
Study Locations
-
-
-
Taipei, Taiwan, 100
- Recruiting
- Ntional Taiwan University Hospital
-
Contact:
- Bor-Sheng Ko, PhD
- Phone Number: 63576 886-23123456
- Email: kevinkomd@gmail.com
-
Contact:
- Brook Chung, MSc
- Phone Number: 886-87297521
- Email: brook.chung@mundipharma.com.tw
-
Principal Investigator:
- Bor-Sheng Ko, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 20 years of age, inclusive
Patients with histologically/cytologically confirmed PTCL using either: NCCN diagnosis criteria, the Revised European American Lymphoma (REAL), and World Health Organization (WHO) disease classification (PTCL histology/cytology subtypes diagnosed by site investigators, PTCL histology/cytology subtypes rechecked by study central pathology lab):
- At least 5 patients with Peripheral T-cell lymphoma, NOS
- At least 5 patients with Angioimmunoblastic T-cell lymphoma
- At least 5 patients with Extranodal NK/T-cell lymphoma, nasal type
- Enteropathy-type T-cell lymphoma
- Hepatosplenic T-cell lymphoma
- Subcutaneous panniculitis-like T-cell lymphoma
- Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)
Patients with documented progressive disease (PD) failed after prior treatment
- Patients may not have received an experimental drug as their only prior therapy
- Patient has had at least 1 biopsy from initial diagnosis of PTCL or in the relapsed setting to confirm PTCL subtypes
- Patient has recovered from the toxic effects of prior therapy
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
- Adequate hematological, hepatic, and renal function as defined by: absolute neutrophil count (ANC) ≥ 1000/µL, platelet count ≥ 100,000/µL (and ≥ 50,000/µL for any following dose), total bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 X upper limit of normal (ULN) (AST/ALT < 5 X ULN if documented hepatic involvement with lymphoma), creatinine ≤ 1.5 mg/dL or a calculated creatinine clearance ≥ 50 mL/min.
- Women of childbearing potential must agree to practice medically acceptable contraceptive regimen from 30 days prior to study treatment initiation until at least 30 days after the last administration of pralatrexate and must have had a negative serum pregnancy test within 14 days prior to the first day of study treatment. Patients who are postmenopausal for at least 1 year (> 12 months since last menses) or were surgically sterilized do not require this test.
- Men who are not surgically sterile must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 90 days after the last administration of pralatrexate.
- Patient has provided written informed consent (IC)
Exclusion Criteria:
Patient has following subtypes (histologically/cytologically confirmed) of PTCL
- Anaplastic large cell lymphoma, ALK +/-
- Patient has: Precursor T/NK neoplasms, with the exception of blastic NK lymphoma
- T-cell prolymphocytic leukemia (T-PLL)
- T-cell large granular lymphocytic leukemia
- Mycosis fungoides and transformed mycosis fungoides
- Sézary syndrome
- Primary cutaneous CD30+ disorders: Anaplastic large cell lymphoma and lymphomatoid papulosis
- Patient has: Extranodal NK/T-cell lymphoma, nasal type with local recurrence
- Active concurrent malignancy (except for non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 5 years.
- Congestive heart failure Class III/IV according to the New York Heart Association's Heart Failure guidelines.
- Patients with human immunodeficiency virus (HIV)-positive diagnosis and are receiving combination anti-retroviral therapy.
- Current or the history of brain metastases or central nervous system (CNS) diseases
- Have undergone allogeneic stem cell transplant
- Relapsed less than 75 days from time of autologous stem cell transplant
- Patients with uncontrolled hypertension, active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the patient to receive protocol treatment
- Had major surgery within 2 weeks of study entry
- Receipt of any conventional chemotherapy or radiation therapy (RT) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the course of the study
- Receipt of corticosteroids within 7 days of study treatment, unless patient has been taking a stable dose of no more than 10 mg/day of prednisone for at least 1 month
- Use of any investigational drug, biologic modifier, or device within 4 weeks prior to study treatment or planned use during the course of the study
- Previous exposure to pralatrexate
- Other conditions that investigators consider not suitable for study enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pralatrexate treatment
Pralatrexate will initially be administered at a dose of 30 mg/m2/week on days 1, 8, 15, 22, 29 and 36 for 6 weeks in a 7-week cycle (cycle: 6 weeks + 1 week rest).
The scheduled date can be done within a window time of plus or minus 1 day
|
This is a single arm study.
Pralatrexate will be administered via IV over 3-5 minutes into a IV line containing normal saline (0.9% sodium chloride, NaCl) with the initial dose of 30 mg/m2/week on days 1, 8, 15, 22, 29, and 36 for 6 weeks in a 7-week cycle.
The scheduled date can be done within a window time of plus or minus 1 day.
The pralatrexate dose may be reduced to 20 mg/m2/week or omit if a patient experiences adverse events.
Pralatrexate administration can be up to 5 cycles or until subject meets withdrawal criteria.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate
Time Frame: Up to 35 weeks
|
Objective response rate (ORR) to pralatrexate treatment in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)
|
Up to 35 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: Up to 40 weeks
|
Incidence of adverse events (AE) and serious adverse events (SAE) emergent from the treatment
|
Up to 40 weeks
|
Overall survival
Time Frame: Up to 5 years
|
Duration of overall survival (months)
|
Up to 5 years
|
Progression-free survival
Time Frame: Up to 5 years
|
Duration of PFS (months)
|
Up to 5 years
|
Completion response rate
Time Frame: Up to 5 years
|
The percentage of CR
|
Up to 5 years
|
Partial response rate
Time Frame: Up to 5 years
|
The percentage of PR
|
Up to 5 years
|
Duration of CR and PR
Time Frame: Up to 5 years
|
Duration of completion response and partial response (days)
|
Up to 5 years
|
Treatment duration
Time Frame: Up to 35 weeks
|
Treatment duration with pralatrexate in the patients without HSCT who achieve CR or PR
|
Up to 35 weeks
|
Hematopoietic stem cell transplant (HSCT)
Time Frame: Up to 5 years
|
Percentage of patients who undergo HSCT
|
Up to 5 years
|
1-year OS rate after HSCT
Time Frame: Up to 1 year
|
1-year overall survival rate after conducting HSCT
|
Up to 1 year
|
1-year PFS rate after HSCT
Time Frame: Up to 1 year
|
1-year progression-free survival rate after conducting HSCT
|
Up to 1 year
|
1-year relapse rate after HSCT
Time Frame: Up to 1 year
|
1-year relapse rate after conducting HSCT
|
Up to 1 year
|
2-year OS rate after HSCT
Time Frame: Up to 2 years
|
2-year overall survival rate after conducting HSCT
|
Up to 2 years
|
2-year PFS rate after HSCT
Time Frame: Up to 2 years
|
2-year progression-free survival rate after conducting HSCT
|
Up to 2 years
|
2-year relapse rate after HSCT
Time Frame: Up to 2 years
|
2-year relapse rate after conducting HSCT
|
Up to 2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Bor-Sheng Ko, PhD, National Taiwan University Hospital
Publications and helpful links
General Publications
- Savage KJ. Peripheral T-cell lymphomas. Blood Rev. 2007 Jul;21(4):201-16. doi: 10.1016/j.blre.2007.03.001. Epub 2007 May 18.
- Shustov A. Novel therapies for peripheral T-cell lymphomas. Ther Adv Hematol. 2013 Jun;4(3):173-87. doi: 10.1177/2040620713481980.
- Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD; International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008 Jun 15;111(12):5496-504. doi: 10.1182/blood-2008-01-134270. Epub 2008 Apr 2.
- Society TLL, Peripheral T-Cell Lymphoma Facts, 2014.
- Wang ES, O'Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma. 2003 Jun;44(6):1027-35. doi: 10.1080/1042819031000077124.
- Krug LM, Ng KK, Kris MG, Miller VA, Tong W, Heelan RT, Leon L, Leung D, Kelly J, Grant SC, Sirotnak FM. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res. 2000 Sep;6(9):3493-8. Erratum In: Clin Cancer Res 2001 Apr;7(4):1102.
- O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011 Mar 20;29(9):1182-9. doi: 10.1200/JCO.2010.29.9024. Epub 2011 Jan 18.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FOT14-TW-401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral T Cell Lymphoma
-
The First Affiliated Hospital of Xiamen UniversityThe First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsRecruitingPeripheral T Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma | Refractory T-Cell LymphomaChina
-
National Cancer Centre, SingaporeMerck Sharp & Dohme LLC; National Medical Research Council (NMRC), SingaporeNot yet recruitingRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaSingapore
-
The Lymphoma Academic Research OrganisationCompletedRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaFrance, Belgium
-
Millennium Pharmaceuticals, Inc.CompletedRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaUnited States, France, Italy, Poland, United Kingdom, Belgium, Germany, Spain, Belarus, Israel, Portugal, Bulgaria, Turkey, Canada, New Zealand, Peru, Brazil, Russian Federation, Chile, Puerto Rico, Australia, Austria, Hungary, Nether... and more
-
University of Alabama at BirminghamTerminatedAnaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T-cell Lymphomas | Adult T-cell Leukemia | Adult T-cell Lymphoma | Peripheral T-cell Lymphoma Unspecified | T/Null Cell Systemic Type | Cutaneous t-Cell Lymphoma With Nodal/Visceral DiseaseUnited States
-
Legend Biotech USA IncActive, not recruitingT-Cell Lymphoma | Peripheral T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Recurrent | Peripheral T-Cell Lymphoma RecurrentUnited States
-
Karyopharm Therapeutics IncTerminatedCutaneous T-cell Lymphoma (CTCL) | Peripheral T-cell Lymphoma (PTCL)Australia, Singapore
-
BeiGeneCompletedCutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditionsChina, Taiwan, Germany, France, Canada, Italy
-
SciTech Development, LLCRush University Medical CenterRecruitingMycosis Fungoides | Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Cutaneous/Peripheral T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Classified | Primary Cutaneous T-cell Lymphoma | Cutaneous T-Cell Lymphoma, Unspecified | Follicular... and other conditionsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingAngioimmunoblastic T-cell Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma | Follicular T-Cell Lymphoma | Nodal Peripheral T-Cell Lymphoma...United States
Clinical Trials on Pralatrexate
-
Samsung Medical CenterCompletedRelapsed or Refractory Peripheral T-cell LymphomaKorea, Republic of
-
Acrotech Biopharma Inc.CompletedPeripheral T-cell LymphomaUnited States, United Kingdom, Canada, France, Italy, Belgium
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Completed
-
Stanford UniversityNational Comprehensive Cancer NetworkCompletedMultiple MyelomaUnited States
-
Acrotech Biopharma Inc.Axis Clinicals LimitedCompletedPeripheral T-Cell Lymphoma (PTCL)United States
-
Spectrum Pharmaceuticals, IncTerminatedPeripheral T-cell LymphomaBelgium, Spain, United States, Australia, France, Israel, Canada, United Kingdom, New Zealand, Italy, Ireland, Poland, Puerto Rico
-
Jennifer AmengualColumbia UniversityWithdrawnLymphoma, T-Cell, Peripheral
-
Jennifer AmengualCompletedLymphoma | Multiple Myeloma | Hodgkin Lymphoma | Lymphoid Malignancies | Non-hodgkin LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Acrotech Biopharma Inc.Withdrawn